Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 14/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004574 | 0.79 | PLA2G7 (0.67) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL10733224 | 0.77 | LMNA (0.44) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL10735501 | 0.74 | PLA2G7 (0.66) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL7708557 | 0.72 | PLA2G7 (0.64) | LMNAPLA2G7 | |
| SCHEMBL10734739 | 0.72 | LMNA (0.48) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL10653223 | 0.71 | PLA2G7 (0.52) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL10618910 | 0.71 | PLA2G7 (0.71) | PLA2G7 | |
| SCHEMBL11064646 | 0.71 | NR3C1 (0.35) | NR3C1 | |
| SCHEMBL10796191 | 0.71 | NR3C1 (0.45) | NR3C1 | |
| SCHEMBL10653116 | 0.70 | PLA2G7 (0.48) | KDM6BKDM4AKDM4DHIF1ANKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103347864-B | Pyrimidone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA 2 | 葛兰素集团有限公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-4521418-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-06-04 | — | — | US | disclosed |
| EP-0015138-B1 | PYRIMIDONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-03-16 | — | — | EP | disclosed |
| EP-0015138-A1 | Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
| US-4216318-A | HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
| US-4154834-A | HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | KDM6B 4389/4885KDM4A 4027/4885KDM4D 4043/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | KDM6B 4389/4885KDM4A 4027/4885KDM4D 4043/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | KDM6B 3632/4885KDM4A 2728/4885KDM4D 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.